JAIN FOUNDATION
Project CNNM2
JAIN FOUNDATION
Project CNNM2
Our Mission
Project CNNM2 began with the diagnosis of a child in our family. Born in 2022, he was a happy, thriving baby until seizures and developmental delays began around his first birthday. After a long search for answers, we learned he has a rare change in his CNNM2 gene.
Our goal is simple and urgent: to build a future with better options for him and for every child living with CNNM2-related conditions.
Scientific Advisory Board
All proposal evaluations and funding decisions are conducted exclusively by our in-house scientific team. This dedicated focus on a single disease area has enabled the Jain Foundation to serve as a center of excellence, maintaining a comprehensive, up-to-date view of the CNNM2 research landscape and promoting collaboration among previously unconnected investigators.

Plavi Jain Mittal, PhD
Executive Director and CSO, Project CNNM2

Audrey Ostenson
Director of Research and Data Strategies
.
Supported by the Jain Foundation Dysferlin Team
Project CNNM2 is intentionally small and focused, but we are not working in isolation. The broader Jain Foundation team continues to advise us, open doors to collaborators, and cheer us on as we build the CNNM2 field.
Akshay Jain
Chairman and CEO

Douglas Albrecht
Co-President

Laura Rufibach
Co-President

Sarah Shira Emmons
Vice President of Patient Affairs & Community Strategies

Bradley Williams
Director of Research & Diagnostic Innovation

Joshua Thayer, Esq.
General Counsel

Laurie Long
Sr. Manager, Operations and Patient Affairs















